Oura Will Pay $625 Million for AI Health Startup Counsel Health

Oura has agreed to acquire Counsel Health for $625 million, the company announced alongside its quarterly earnings today, marking one of the largest bets by a wearables maker on clinical AI and direct physician access. The deal, which Oura expects to close before the end of the year, follows the integration of Counsel's AI chatbot into the Oura app earlier this year.

The price tag is the concrete signal here: a consumer wearables company is now spending more than half a billion dollars not on sensors or hardware, but on software that turns biometric readings into medical conversations. That shift matters for a health-tracking market where the line between wellness data and clinical care is increasingly contested — and where regulators, insurers, and consumers are still deciding who is allowed to act on wearable data.

What does Counsel Health actually do?

Counsel Health describes itself as an "AI-native primary care company." Its chatbot delivers AI-generated responses and insights based on users' health data reported from their wearables. When the AI's answer is not enough, the conversation can proceed to one of Counsel's in-house physicians — a human doctor reachable directly through the app.

The mechanics, as described in the announcement:

• AI-generated responses draw on biometric data from the user's Oura ring
• Users can escalate to a real physician from within the app
• Counsel's physician network currently stands at "about 50 people," according to CEO Muthu Alagappan, speaking to Bloomberg
• Counsel's 70 employees will join Oura as part of the deal

The caveat is structural, not incidental. A 50-physician network serving a wearables user base that spans millions of rings is a thin layer of human clinical capacity, and the announcement says nothing about how quickly that network can scale or how physician availability will be guaranteed once the integration goes live for all users. Alagappan says the company plans to expand the on-demand physician network, but no target numbers or timelines appear in the announcement.

Why is Oura spending this much on medical AI?

Oura CEO Tom Hale framed the acquisition in an interview with Bloomberg as part of a plan to connect three things: wearables, clinical AI, and access to doctors, all built on insights from biometric data. In practice, that means the ring's continuous measurements — the data stream Oura already collects — would feed an AI layer that can answer medical questions or monitor ongoing conditions, with a physician available when the situation requires one.

The company's press release lays out three care areas the combined service will focus on:

• Preventative care — intervening before conditions develop, using long-term biometric trends
• Acute care — handling episodic health concerns as they arise
• Specialty and chronic care — ongoing management of conditions including reproductive health and cardiometabolic health

Each of the three areas represents a different commercial logic. Preventative care monetizes the data Oura already collects; acute care competes with telehealth incumbents on speed; chronic care is where continuous biometric monitoring arguably has the most clinical value, and also where the regulatory and liability stakes are highest. The announcement does not say which area will launch first, what the service will cost users, or how it will be reimbursed — questions that will determine whether the $625 million price is justified.

Who is running the clinical AI effort?

As part of the deal, Counsel Health CEO Muthu Alagappan will become Oura's chief clinical AI officer. The title itself is a signal: Oura is creating a C-suite position specifically for AI that operates in a medical context, a role that barely existed at consumer hardware companies a few years ago.

Counsel's 70 employees join Oura alongside him. That headcount, against the $625 million price, implies Oura is buying technology, physician relationships, and market position rather than teams alone. What Oura is not buying, based on the announcement, is exclusivity over Counsel's platform.

Will Counsel keep serving other customers?

Yes — and that is one of the more consequential details in the announcement. Oura says Counsel will continue offering its medical AI platform outside Oura's user base through new and existing enterprise partners, including "health plans, health systems, consumer health organizations, and employers."

That structure means Oura is acquiring a clinical AI vendor that still operates as a vendor. Health plans and employers using Counsel's platform will now sit downstream of a company whose primary business is selling smart rings. Whether those enterprise partners view a ring maker as a neutral clinical AI provider is an open question the announcement does not address. For Oura, though, keeping Counsel's enterprise business alive creates a second revenue stream that could offset the acquisition cost independently of ring sales.

What is the context for a deal of this size?

The acquisition lands at a moment when wearables companies are under pressure to prove that their data has medical value rather than merely lifestyle value. A ring that tells you about your sleep is a consumer product; a ring whose data triggers a physician consult, monitors a cardiometabolic condition, or supports reproductive health management is something closer to a care delivery platform — with correspondingly higher expectations for accuracy, safety, and accountability.

Hale's described plan — biometric data feeding AI triage feeding human doctors — is the sequence most large health systems and insurers are also experimenting with. Oura's differentiator is that it already owns the continuous data layer and, after this deal, the physician network to act on it. What Oura has not demonstrated yet, in this announcement or elsewhere in the source material, is clinical evidence that AI-guided care built on ring data improves outcomes, or how it will handle the diagnostic limits of consumer-grade sensors.

What happens next?

The deal is expected to close before the end of the year. After that, the practical tests arrive: pricing, physician availability at scale, regulatory posture for AI-generated medical answers, and the first evidence — or absence — of clinical results. Oura has now committed $625 million to the proposition that the future of primary care starts on a finger; the burden of proof sits with the roughly 50 physicians and 70 employees who just joined the company.